Jefferies says Elan (ELN +6.5%) should start moving ahead of the bapineuzumab Phase 3 data,...


Jefferies says Elan (ELN +6.5%) should start moving ahead of the bapineuzumab Phase 3 data, which the firm expects in July. Jefferies estimates a 75% of FDA approval for bapineuzumab, but believes expectations are low with little being priced into shares.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs